-

Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia

Grants to Strengthen Prevention Models and Local Systems of Care Nationwide

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced a $12 million investment in 33 community‑based organizations across 14 states and the District of Columbia through its Community Health Worker (CHW) Comprehensive HIV Prevention Initiative. This two‑year effort expands CHW‑led prevention models that strengthen knowledge, care navigation, and access to services for communities disproportionately affected by HIV.

GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS 14 STATES AND THE DISTRICT OF COLUMBIA

Share

“Community health workers are often the first and most trusted point of connection for people seeking information, support and care,” said Keeley Cain Wettan, Executive Vice President, General Counsel, Legal and Compliance at Gilead Sciences and a Board Member of Gilead Foundation. “Advancing HIV prevention requires both medical innovation and strong, community-led systems that address the social and structural barriers people face every day. By investing in community-based organizations, we’re helping expand access to trusted information, screenings, and culturally responsive care that can drive more equitable health outcomes.”

The initiative also strengthens organizational infrastructure and CHW training systems to build sustainable, locally driven HIV‑prevention networks. It prioritizes communities most impacted by HIV—including Black and Latino communities who have sex with men (MSM); cisgender and transgender women; people who inject drugs; and youth—by delivering tailored education and prevention services.

The 33 recipient organizations represent a diverse range of communities facing ongoing HIV prevention challenges. Awardees demonstrate strong community trust, thoughtful program design, and clear plans for measurable impact. Many will use culturally aligned approaches such as promotores models, support, and navigation services within Latino communities, along with peer ambassadors and youth‑focused programming.

Philadelphia‑based grantee Bebashi – Transition to Hope, which works to advance health equity in the communities it serves, shared its enthusiasm for the initiative. “Bebashi is ecstatic to receive this grant from Gilead Foundation which will strengthen our efforts through the Community Health Worker Initiative,” said Frank Franklin, Ph.D., J.D., M.P.H., FCPP, Chief of Strategic Initiatives. “Community health worker professionals complement Bebashi’s mission of community responsiveness and holistic support.”

Over the next two years, funded organizations will work to:

  • Expand integrated screening for HIV, STIs, mental health, and substance use
  • Deliver targeted HIV prevention education
  • Connect people to services, including HIV prevention, harm reduction resources, and other supportive care
  • Reduce stigma and strengthen community engagement through trusted massagers

Grantee Allies in Hope, a Houston‑based nonprofit providing HIV prevention, testing, and supportive services to communities disproportionately impacted by HIV, emphasized the role of connection in prevention. “When communities are supported, informed, and empowered, pathways to hope become pathways to healing,” said Jeffrey Campbell, Chief Executive Officer. “Our mission to end the HIV epidemic in the greater Houston area will be significantly bolstered through this funding.”

Many programs will also strengthen the community health workforce through peer navigator models, apprenticeships, pharmacy‑based training, and community health integration across care settings, building long‑term capacity beyond the grant period.

Grantees

Alabama

Five Horizons Health Service

Thrive Alabama

 

Arizona

Association (NPhA)

Prisma Community Care

National Pharmaceutical

 

California

Bienestar Human Services

Realistic Education in Action Coalition to Foster Health (R.E.A.C.H. LA)

St. John’s Community Health

The TransLatin@ Coalition

 

Colorado

Servicios de La Raza

 

Florida

LGBT+ Center Orlando

Oceana Community Health, Inc

Prevention 305

The Poverello Center, Inc.

Georgia

NAESM, Inc

 

Illinois

Chicago Family Clinic, Inc

 

Louisiana

CrescentCare

 

Michigan

Community Health Awareness Group (CHAG)

 

New York

Callen-Lorde Community Health Center

Voces Latinas Corporation

Cicatelli Associates, Inc. (CAI) programs nationwide

Gay Men’s Health Crisis (GMHC)

Trillium Health, Inc

Ohio

Equitas Health

 

Pennsylvania

Bebashi – Transition to Hope

Mazzoni Center

 

Texas

Abounding Prosperity, Inc.

Allies in Hope

Prism Health North Texas

PILLAR

Resource Center of Dallas, Inc.

 

Washington, DC

La Clínica del Pueblo, Inc.

Whitman-Walker Health

 

 

 

About the Gilead Foundation

The Gilead Foundation is a nonprofit organization that works to create a thriving health ecosystem. The Gilead Foundation takes a holistic approach to mitigate the root causes of health inequities by providing resources to organizations that empower people with the skills to be their own best advocate and create systems of support that strengthen communities, classrooms and workplaces

About Gilead Sciences

Gilead Sciences, Inc. (Nasdaq: GILD) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Contacts

Elizabeth Baxter, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

Gilead Sciences, Inc.

NASDAQ:GILD

Release Summary
GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US
Release Versions

Contacts

Elizabeth Baxter, Media
public_affairs@gilead.com

Jacquie Ross, Investors
investor_relations@gilead.com

Social Media Profiles
More News From Gilead Sciences, Inc.

Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new Phase 3 ARTISTRY-1 and ARTISTRY-2 trial data at CROI 2026 showing a treatment switch to an investigational, single-tablet combination regimen of bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) was effective in people living with HIV with virological suppression, including those switching from complex multi-tablet regimens or a global guideline-recommended single-tablet regimen. The n...

Gilead Sciences to Present at Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: TD Cowen Annual Health Care Conference on Tuesday, March 3 at 11:10 AM Eastern Time Leerink Partners Global Healthcare Conference on Tuesday, March 10 at 11:20 AM Eastern Time Barclays Annual Global Healthcare Conference on Wednesday, March 11 at 11:00 AM Eastern Time The live webcasts can be accessed at the company’s investors pa...

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

FOSTER CITY, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incura...
Back to Newsroom